First 90 Days: Launch Checklist

Most people searching for a downstream processing business plan already know the science. What trips up first-time founders is sequencing: which approvals gate which purchases, and which purchases gate the first signed client. Here is the order that actually works, based on how launch-stage process-development labs get from zero to their first invoice.

• Weeks 1-4: Incorporate, open a business bank account, and draft the technical scope (which downstream unit operations you'll offer: capture chromatography, TFF/UF, viral clearance, or full polish trains). Start GMP consultancy conversations now - this is the longest lead-time item.
• Weeks 4-10: Submit MHRA MIA application (UK) or begin FDA establishment registration prep (US). Source shared cleanroom or incubator lab space rather than building your own - Stevenage Bioscience Catalyst, BioCity Nottingham, and similar UK bioincubators lease bench and suite space to exactly this kind of startup.
• Weeks 8-14: Order the chromatography system and single-use bioreactor/TFF skid. Lead times on AKTA-class systems commonly run 8-12 weeks, so this needs to be placed before, not after, your first client conversation closes.
• Weeks 10-16: Recruit your first process scientist and QA lead. In a 3-person launch team, the QA hire is usually the hardest to fill and the most important for winning GMP-adjacent work.
• Weeks 14-20: Run a mock technology-transfer exercise with a friendly academic spin-out or early-stage biotech to validate your SOPs before your first paying engagement.
• Weeks 16-26: MHRA inspection (if applicable) and first client contract signed. Budget for a 3-6 month gap between application submission and inspection.
• Month 7 onward: First fee-for-service downstream processing project delivered; begin tracking utilisation rate as your core operating KPI.

The single biggest scheduling risk is treating licensing and equipment procurement as sequential rather than parallel. Both take 2-4 months; run them side by side and you compress your time-to-first-invoice by roughly a quarter.

It's worth building slack into every one of these windows. Founders who have been through this launch sequence before consistently tell us the same thing: the calendar risk isn't in any single step, it's in the handoffs between steps. A chromatography system that arrives on schedule but two weeks after your process scientist starts is two weeks of paid idle time. An MHRA inspection that gets rescheduled by six weeks (which happens more often than applicants expect) pushes your first invoice further than the six weeks alone would suggest, because your first client's own internal approval cycle has to restart too. Build a two-to-four-week buffer around every handoff in this checklist and treat the 90-day estimate above as the floor, not the target.

Startup Costs & Equipment

A lab-to-pilot scale contract downstream processing operation typically requires $87,000 to $525,000 (£68,000 to £414,000) to reach first revenue. This is a different order of magnitude from a commercial biologics facility, where a 50,000-200,000 litre fermentation plant runs $100 million to $300 million, with median multi-product facility construction costs reaching $185 million in 2024 according to industry capex benchmarking. The template below is scoped to the launch-stage service business, not the mega-facility.

Cost Breakdown

• Single-use bioreactor + TFF/UF skid (lab-to-pilot scale): $29,000-$194,000 (£22,000-£153,000)
• Chromatography system + resin/consumables (AKTA-class): $20,000-$89,000 (£15,000-£70,000)
• Regulatory: FDA registration, GMP consultancy, MHRA MIA prep: $10,000-$94,000 (£7,000-£74,000)
• Product liability, facility & clean-room insurance: $9,000-$63,000 (£7,000-£49,000)
• Process development staff recruitment (scientists, QA): $8,000-$57,000 (£6,000-£45,000)
• Cold-chain warehousing and sample logistics: $6,000-$36,000 (£4,000-£28,000)

Single-use systems dominate launch-stage builds for a reason: they cut installation and cleaning-validation time compared to stainless steel, and they let a new lab flex capacity without committing to a fixed footprint before the client pipeline is proven. Stainless remains cheaper per batch only above roughly 10,000-litre scale, which is well beyond where most launch-stage downstream processing businesses operate.

Where you land within the $87,000-$525,000 range depends mostly on two decisions: whether you buy or lease your bioreactor and chromatography hardware, and whether you take on the regulatory burden of a full GMP-track lab from day one or start as a pre-GMP process-development shop and add licensing once you have a named anchor client. A founder leasing bench time in a shared bioincubator and deferring the MHRA MIA application until client 1 is signed can realistically launch near the $87,000 floor. A founder buying dedicated equipment and pursuing MIA approval pre-emptively, to shorten sales cycles with larger prospective clients who won't engage an unlicensed lab, should plan around the middle to upper end of the range.

Funding Routes

In the UK, Innovate UK Smart Grants (up to £500,000 for late-stage R&D projects) and the Start Up Loans scheme (up to £25,000 at 6% fixed) are the two most common early routes, often blended as founders top up an Innovate UK grant with a personal loan to cover working capital. In the US, SBA 7(a) loans cover up to $5 million with terms up to 25 years, though lenders will expect a validated technical plan and named anchor client before underwriting a lab-equipment-heavy application. Our bespoke business plan service includes SBA-compliant formatting and lender-ready financial projections. Life-science-focused venture and grant funding (Wellcome Trust Innovator Awards, BBSRC Follow-on Fund) is also common for UK-based process-development spin-outs with a university connection.

Recommended Equipment & Suppliers

Naming real suppliers in your business plan signals to lenders and investors that you understand the technical landscape, not just the market-size headline. These are the vendors that dominate downstream processing equipment and consumables today:

• Cytiva (Danaher): Chromatography resins used in an estimated 75% of FDA-approved biotherapeutic manufacturing processes, plus AKTA chromatography systems and Whatman/Pall filtration devices and membranes.
• Sartorius Stedim Biotech: Bioreactors, chromatography systems (following its 2022 acquisition of Novasep's chromatography division), and filtration systems built for continuous processing.
• Repligen: Downstream filtration, tangential flow filtration (TFF), and process analytics; partnered with Sartorius in 2023 to integrate its XCell ATF technology with Sartorius bioreactors.
• Thermo Fisher Scientific: More than 30 years of purification-technique development for complex molecules, with end-to-end downstream capability and technology-transfer support that smaller labs often lean on for their first client handoffs.
• MilliporeSigma (Merck Group): Chromatography media, single-use assemblies, and viral clearance validation services.
• Boehringer Ingelheim BioXcellence: A useful reference point for how larger CDMOs structure upstream/downstream service lines - worth studying even if you never compete with them directly at launch scale.

Most launch-stage founders start with a single chromatography system and a rented single-use bioreactor skid, then add capacity as utilisation climbs past 60-70%. Buying a second system before the first is fully booked is the most common capital misallocation we see in early process-development business plans.

Your business plan should also name a secondary or backup supplier for at least your chromatography resin, since a single-source dependency here is one of the first things a technical due-diligence reviewer will flag. Cytiva and MilliporeSigma resins are broadly interchangeable for most standard capture steps, and stating explicitly in your plan that you've qualified two resin sources reduces perceived supply-chain risk without adding meaningful cost. The same logic applies to single-use assembly suppliers: Sartorius and Thermo Fisher both offer compatible bag and tubing formats, so naming both in your operations plan signals resilience rather than indecision.

Licensing: FDA, MHRA & EU GMP

United States

• 21 CFR Part 210/211 GMP compliance - the FDA's current Good Manufacturing Practice regulations for finished drug products (Part 211) and active pharmaceutical ingredients (Part 210). Budget $15,000-$60,000 in consulting and validation costs to reach audit-ready status.
• FDA establishment registration and drug listing - required if you manufacture, process, pack, or hold drugs for commercial distribution in the US; renewed annually.
• Pre-Approval Inspection (PAI) readiness - if your work supports a client's Biologics License Application, the FDA (and often the EMA in parallel) will schedule a 1-2 week on-site audit of your process before approval; a single critical finding can delay or deny the client's application.
• ICH Q5-Q11 compliance - the international guidelines governing characterisation, comparability, and quality-by-design for biologics, which most downstream process-development clients will expect you to work to even pre-GMP.

United Kingdom

• Apply for a Manufacturer's/Importer's Authorisation (MIA) from the MHRA - the core UK licence covering manufacture of human medicines, embedding GMP obligations. Application plus inspection fees typically run £5,000-£15,000 before consultancy costs, with several months from submission to grant, including an on-site inspection for new sites.
• Arrange Qualified Person (QP) oversight for batch certification - either a contracted QP or an in-house hire, commonly $60,000-$110,000/year equivalent.
• Note the MHRA's July 2025 update to decentralised manufacture regulations, which formalises a hub-and-spoke model for modular and point-of-care production - relevant if your downstream service targets cell and gene therapy clients running distributed manufacturing.
• Pure process-development work that never touches a GMP batch destined for human use may sit outside MIA scope initially, but most labs will need one within 12-18 months as clients progress toward clinical batches.

European Union

EU-facing work falls under EudraLex Volume 4 (EU GMP), with compliance to the same ICH Q5-Q11 guidelines as the US and UK. Sterile or aseptic downstream steps (viral inactivation, final formulation) are governed by EU GMP Annex 1, and clinical-stage investigational medicinal product manufacturing falls under Annex 13. If you plan to serve EU clients post-Brexit, budget for a separate EU-recognised manufacturing site or a contracted EU-based partner, since a UK MIA alone does not confer EU manufacturing rights.

One licensing detail that catches out otherwise well-prepared founders: your MHRA or FDA application will ask for a named responsible person and a defined quality system before you've necessarily won your first client, which means the QA hire discussed in the launch checklist above needs to happen earlier than most technical founders instinctively plan for. Budget the QA lead's start date against your licensing submission date, not against your first signed contract. Getting this sequence backwards is the second most common reason, after equipment lead times, that launch-stage downstream processing plans slip their first-revenue date by a full quarter.

Revenue Model & Worked Example

Contract downstream processing work is usually billed one of two ways: as a fee-for-service project (a fixed price per molecule for process characterisation or optimisation, typically $40,000-$250,000) or as capacity-based CDMO fees ($150-$500 per litre of annual production capacity per year, which only applies once you're running at meaningful scale).

Worked Example: A Launch-Stage Lab

A lab-scale contract downstream processing shop running 6 client process-development projects per year at an average fixed fee of $85,000 generates approximately $510,000 in annual revenue. Cost structure typically breaks down as:

• Chromatography resin and single-use consumables: ~28% of revenue
• Scientist and QA payroll: ~42% of revenue
• Facility, validation, and overhead: ~18% of revenue

That leaves a net margin of roughly 8-12% in year one, improving toward 15-17% by year three as utilisation rises and repeat-client work reduces the cost of business development. The margin curve is unusually back-loaded for this business model: the first 2-3 anchor clients are the hardest to win and the least profitable, because a meaningful share of early revenue goes toward proving out SOPs and technology-transfer processes rather than pure delivery.

Additional revenue streams worth modelling separately: analytical testing add-ons (endotoxin, HPLC purity, SDS-PAGE), tech-transfer documentation packages, and retained monthly QA-support contracts once a client moves from development into GMP manufacturing with a separate CDMO.

A useful sanity check for your own model: divide projected annual revenue by the number of billable weeks your lab can realistically run (48 weeks minus planned downtime for validation and maintenance) and compare that to your day rate for a comparable scientist-hour on the open market. If your implied day rate for a fully loaded process-development project comes out below what a freelance bioprocessing consultant charges hourly, your pricing is too low relative to the capital risk you're carrying. Most sustainable launch-stage plans price fee-for-service projects at a 2.5x to 3.5x multiple of the fully loaded cost of the scientist time involved, which is what covers the equipment depreciation and consumables the freelance-consultant comparison doesn't have to absorb.

Choosing Your Service Model

"Downstream processing business" isn't one business model, it's at least three, and the plan you write needs to commit to one before the financials will make sense. Founders coming from a CDMO or academic bioprocessing background often try to write a plan that hedges across all three, which is exactly what makes lenders and grant assessors nervous. Here's how the three most common launch-stage models actually compare.

Most first-time founders searching for this template should be planning the middle row. The consultancy model is a faster route to cash flow but caps out quickly on revenue per client, since you're selling hours rather than lab capacity. The full GMP CDMO model is where the industry's headline $100M+ capex numbers come from, and it is very rarely the right first move for a founder without institutional backing already in place. The lab-scale fee-for-service model is the sweet spot: it lets you charge for both expertise and equipment access, and it's the model that Innovate UK Smart Grants and SBA loans are actually sized to fund.

One detail that changes the entire plan: whether you own the chromatography and TFF equipment outright or lease bench time in a shared bioincubator facility. Owning equipment raises your fixed costs but lets you take on more concurrent projects; leasing bench time lowers your breakeven point but caps your revenue ceiling until you can justify buying your own system. Most successful launch-stage plans we've seen start with leased bench time for the first 8-12 months, then transition to owned equipment once 2-3 anchor clients are secured.

Market Size & Growth

The global downstream processing market was valued at approximately $35.56 billion in 2025, and is projected to reach $112.86 billion by 2034, a compound annual growth rate of 13.72%, according to Precedence Research market data reported via BioSpace. The US downstream processing market alone was estimated at $17.25 billion in 2025, rising to roughly $67.4 billion by 2035, per Nova One Advisor's US market report.

The growth driver behind these figures is not abstract: monoclonal antibodies, vaccines, and recombinant proteins are large, complex molecules that require sophisticated multi-step purification, and downstream processing already represents the largest single share of total biopharmaceutical manufacturing cost. That cost pressure is precisely why fee-for-service and CDMO-style downstream processing businesses exist as a category rather than every biotech building purification capability in-house.

The application mix matters for positioning: monoclonal antibody-related work accounted for an estimated 42% of application share in 2024, with antibiotic production at roughly 34% - a useful data point if your plan targets a specific therapeutic modality rather than generic capacity.

Two structural trends worth citing directly in a business plan's market section, because both work in favour of a launch-stage service provider rather than against it. First, artificial intelligence and machine learning tools are increasingly used to simplify downstream processing decisions, particularly in predicting chromatography resin behaviour and optimising buffer conditions, which lowers the technical barrier for a smaller lab to compete on process efficiency rather than just headcount. Second, the ongoing growth of contract manufacturing organizations as a category is not just a commercial-scale phenomenon: as more biologics programmes get outsourced end-to-end, the process-development work that has to happen before a CDMO contract begins is itself increasingly outsourced too, which is the specific gap a launch-stage downstream processing service is built to fill. Neither trend requires you to compete with Boehringer Ingelheim or WuXi Biologics on scale; both mean the addressable pool of clients who need exactly your kind of help is growing faster than the market's headline CAGR alone would suggest.

Solid-liquid separation techniques are flagged in market analysis as the fastest-growing technique segment, even though chromatography retains the largest overall share. If your lab is equipping for centrifugation, depth filtration, or flocculation capability alongside chromatography, that's a defensible point of differentiation to highlight in your plan's competitive-positioning section rather than an afterthought equipment line.

Where Downstream Processing Demand Concentrates

Location matters more for this business than for most services, because clients want proximity to their own R&D sites and to a talent pool with bioprocessing experience.

North America still holds the largest share of global demand at roughly 36%, but Asia-Pacific is growing fastest, driven heavily by China's biomanufacturing expansion. A UK-based launch-stage lab competing on cost and turnaround time against APAC capacity should lean into proximity and regulatory familiarity (MHRA-aligned documentation from day one) as its defensible edge, rather than trying to compete on price per litre.

Your business plan's location section should also address the talent question directly, since it's usually the binding constraint on growth rather than lab space or equipment. Process scientists with hands-on chromatography and TFF experience are in short supply relative to demand in every cluster listed above, and a launch-stage lab competing against Cytiva, Sartorius, or a well-funded CDMO for the same regional talent pool needs a credible answer for why a scientist would join a three-person startup instead. The honest answers that work in practice: broader technical ownership than a large CDMO offers a junior hire, equity or profit-share arrangements a corporate employer can't match, and proximity to a specific academic supervisor or research group the candidate already has ties to. Whichever of these applies to your situation, name it explicitly in the management-team section of your plan rather than leaving hiring as an unaddressed risk.

Common Mistakes First-Time Founders Make

We've reviewed enough downstream processing and adjacent bioprocessing business plans to see the same five mistakes recur, almost always because the founder is a strong scientist writing their first commercial document.

• Sizing equipment for peak demand, not year-one reality. Buying a chromatography system rated for 500-litre batches when your realistic first-year client base needs 50-litre runs strands capital that should have gone into working capital or a second hire.
• Underestimating consumables spend. Chromatography resin and single-use assemblies commonly run 25-30% of revenue, yet many first-draft financial models bury this inside a generic "cost of goods" line at 10-15%, which quietly overstates margin by half.
• Applying for MHRA MIA or FDA registration only after signing the first client. This is the single most common cause of a 3-6 month delay between "signed contract" and "first invoice," and it is entirely avoidable by starting the application in parallel with equipment procurement.
• Treating GMP documentation as a one-time setup cost. Quality assurance is an ongoing headcount line, not a project fee. Plans that show QA spend dropping to zero after year one are a red flag to any lender who has funded a life-sciences business before.
• Ignoring the technology-transfer bottleneck. Most first-year revenue loss in this business comes from delays handing processes back and forth between the client's team and yours, not from lab capacity constraints. A realistic plan budgets extra calendar time for tech transfer on every new client relationship, especially the first one.

The pattern underneath all five: founders model the science accurately and the commercial mechanics optimistically. A lender or grant panel reviewing your business plan wants to see that you've made the reverse mistake at least once in your own head, on paper, before they'll take the numbers seriously.

Glossary of Downstream Processing Terms

If you're writing this plan for a bank manager, grant panel, or angel investor who isn't a bioprocessing specialist, these are the terms worth defining in your own appendix.

• Capture chromatography: The first purification step after harvest, typically using a resin (such as Protein A for antibodies) that selectively binds the target molecule and lets impurities pass through.
• Polishing chromatography: A second or third chromatography step that removes remaining trace impurities and product variants after capture, bringing purity up to pharmacopoeial standards.
• Tangential flow filtration (TFF): A membrane-based technique used to concentrate the product and exchange it into a new buffer, run in a loop rather than a single pass.
• Viral inactivation/clearance: A mandatory regulatory step (usually low pH treatment or nanofiltration) that demonstrates a biologic manufacturing process removes or inactivates any adventitious virus to a validated log-reduction level.
• Technology transfer: The formal process of moving a validated method from a development lab to a manufacturing site (or from your lab to a client's), including documentation, training, and comparability testing.
• Single-use systems: Pre-sterilised, disposable bioprocessing equipment (bags, tubing, bioreactor liners) that replace fixed stainless-steel vessels, cutting cleaning-validation time and cross-contamination risk at the cost of higher recurring consumable spend.
• Qualified Person (QP): A UK/EU regulatory role responsible for certifying that each batch of medicinal product has been manufactured and tested in compliance with GMP and the marketing authorisation, before it can be released.
• Utilisation rate: The percentage of available lab/equipment capacity actually billed to clients in a given period; the single most important operating KPI for a fee-for-service downstream processing business.

Sample Business Plan Preview

Here's an extract from a downstream processing business plan structure written by our team, so you can see exactly what you'll get:

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for your industry:

• Executive Summary - Your business at a glance, written to hook investors or lenders in 60 seconds
• Company Overview - Legal structure, ownership, facility location, and founding story
• Industry Analysis - Market size, growth trends, and the regulatory landscape specific to downstream processing
• Customer Analysis - Target biotech/CDMO segments, project economics, and buying triggers
• Competitor Analysis - Positioning against larger CDMOs and equipment-vendor service arms
• Marketing Plan - Channels for reaching biotech R&D leads, conference presence, and referral partnerships
• Operations Plan - Equipment, cleanroom logistics, staffing structure, and technology-transfer workflows
• Management Team - Founder and technical team bios, scientific advisory board, and key hires planned

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, and startup capital requirements - built around the equipment and staffing costs specific to a downstream processing operation, not a generic manufacturing template.

Frequently Asked Questions

Related Business Plan Templates

If downstream processing isn't an exact fit for your venture, these adjacent templates may be closer to what you're building:

• Biotech Drug Discovery Business Plan Template - for earlier-stage discovery and target-identification businesses upstream of process development
• Bioanalytical Testing Services Business Plan Template - for labs offering analytical characterisation rather than process/purification work
• Business Plan Writer - if you'd rather talk through your specific downstream processing model with a consultant before committing to a structure